Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22–23, 2017, Bethesda, USA
Gliomatosis cerebri (GC) is an aggressive glioma characterized by an invasive growth pattern and a dismal prognosis. The low incidence and non-specific symptoms at presentation pose unique challenges for early diagnosis and disease-specific research. There is no standard of care for the treatment of patients with a GC phenotype. Understanding the biology of this entity is a critical step in determining effective treatments. Toward this end, the Second International GC Group convened at National Institutes of Health, Bethesda on June 22nd–23rd 2017. This paper summarizes the main conclusions and recommendations for research priorities to fight this fatal condition.
KeywordsGliomatosis cerebri Meeting Consensus Second International Gliomatosis cerebri Meeting 2017
List of scientific participants of the Second International Gliomatosis cerebri Group Meeting, June 22–23, 2017, Bethesda, USA: Kenneth Aldape, University Health Network, Canada; Marta Alonso, University Hospital of Navarra, Spain; Terri Armstrong, National Cancer Institute, USA; Timothy Bentley, Purdue University College of Veterinary Medicine, USA; Veronica Biassoni, Fondazione IRCCS Instituto Nazionale dei Tumori, Italy; Anne-Florence Blandin, University of Strasbourg, France; Alberto Broniscer, St. Jude Children’s Research Hospital, USA; David Castel, Gustave Roussy/CNRS, France; Kenneth Cohen, Johns Hopkins Hospital, USA; Benjamin Deneen, Baylor College of Medicine, USA; Ira Dunkel, Memorial Sloan Kettering Cancer Center, USA; Natacha Entz-Werle, CHU Strasbourg, France; Gerrit H. Gielen, University Hospital Bonn, Germany; Mark Gilbert, National Cancer Institute, USA; Stewart Goldman, Northwestern University, USA; Jeffrey Greenfield, Weill Cornell Medicine, USA; Cynthia Hawkins, The Hospital for Sick Children, Canada; Chris Jones, The Institute of Cancer Research, UK; Yasmin Khakoo, Memorial Sloan Kettering Cancer Center, USA; Mark Kieran, Dana Farber Cancer Institute, USA; Amy LeBlanc, National Cancer Institute, USA; Rishi Lulla, Northwestern University, USA; Peter Manley, Dana Farber Cancer Institute, USA; Dragan Maric, National Cancer Institute, USA; Michelle Monje, Stanford University, USA; Andres Morales La Madrid, Hospital Sant Joan de Deu, Spain; Giovanni Morana, Istituto Giannina Gaslini, Italy; Edjah Nduom, National Cancer Institute, USA; Hideho Okada, University of California San Francisco, USA; Roger Packer, Children’s National Health System, USA; Surabhi Ranjan, National Cancer Institute, USA; David Reardon, Dana-Farber Cancer Institute, USA; Karlyne Reilly, National Cancer Institute, USA; Elisabetta Schiavello, Fondazione IRCCS Instituto Nazionale dei Tumori, Italy; Jack Shern, National Cancer Institute, USA; Katherine Warren, National Cancer Institute, USA; Patrick Wen, Dana-Farber Cancer Institute, USA; Jing Wu, National Cancer Institute, USA. We gratefully acknowledge the support provided by the following GC advocacy and research collaboratives: Anne un rayon de soleil, AYJ Fund, Children’s Brain Tumor Foundation, Elizabeth’s Hope, Fey y Misericordia, Franck un rayon de soleil, Izas la Princesa Guisante, Joshua Bembo Project, Kelly and Kyle Fisher, Mathys un rayon de soleil, Robert and Heather Jucha and Rudy A Menon Foundation. We thank the National Institutes of Health for co-sponsoring this meeting. This research was supported by the Intramural Research Program of the National Institutes of Health.
Compliance with ethical standards
Conflict of interest
The authors disclose that there is no conflict of interest.
- 8.Soffietti R, Rudà R, Laguzzi E et al (2007) Treatment of Gliomatosis cerebri with temozolomide: a retrospective study of the AINO (Italian Association for Neuro-Oncology). In: ASCO Annual Meeting Proceedings 2007: 2033Google Scholar
- 18.Hipp SJ, Goldman S, Kaushal A et al (2016) A Phase I trial of lenalidomide and radiotherapy in children with newly diagnosed diffuse intrinsic pontine gliomas and high-grade gliomas. Paper presented at International Symposium on Pediatric Neuro-Oncology; June, 2016; Liverpool, UKGoogle Scholar